By Colin Kellaher

 

Sanofi SA on Tuesday said a phase 3 study of Sarclisa added to the standard-of-care treatment of carfilzomib and dexamethasone met the primary endpoint at its first planned interim analysis in patients with relapsed multiple myeloma.

The Paris drug maker said the addition of Sarclisa showed significantly prolonged progression-free survival compared to carfilzomib and dexamethasone alone in patients with the blood cancer.

Sanofi said there were no new safety signals identified in the study, the second positive phase 3 trial for Sarclisa, adding that it expects the study results to form the basis of regulatory submissions planned for later this year.

Sarclisa is approved in the U.S. in combination with pomalidomide and dexamethasone for the treatment of adults with relapsed refractory multiple myeloma who have received at least two prior therapies.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

May 12, 2020 09:04 ET (13:04 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Oct 2020 to Oct 2020 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Sanofi Charts.